Literature DB >> 7811044

Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against Staphylococcus aureus.

C M Brandt1, M S Rouse, B M Tallan, W R Wilson, J M Steckelberg.   

Abstract

Results of in vitro time-kill synergy studies using subinhibitory, inhibitory, or suprainhibitory concentrations of bactericidal agents were compared with treatment outcomes of experimental infective endocarditis due to a methicillin-susceptible strain of Staphylococcus aureus. For rifampin-cephalosporin combinations, in vitro synergy testing using recommended fractions of the MIC failed to predict antagonism in vivo while concentrations above the MIC corresponded with antagonism in vivo.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7811044      PMCID： PMC284709          DOI： 10.1128/AAC.38.9.2191

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Statistical considerations for performing multiple tests in a single experiment. 2. Comparisons among several therapies.

Authors:  P C O'Brien; M A Shampo
Journal:  Mayo Clin Proc       Date:  1988-08       Impact factor: 7.616

2.  Comparison of the antibacterial activity of rifampicin and other antibiotics.

Authors:  W R McCabe; V Lorian
Journal:  Am J Med Sci       Date:  1968-10       Impact factor: 2.378

3.  In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.

Authors:  A Bartoloni; M G Colao; A Orsi; R Dei; E Giganti; F Parenti
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

4.  Antistaphylococcal activity of rifampin with other antibiotics.

Authors:  S H Zinner; H Lagast; J Klastersky
Journal:  J Infect Dis       Date:  1981-10       Impact factor: 5.226

5.  Comparative in-vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM 427, against Staphylococcus aureus.

Authors:  P Van der Auwera; P Joly
Journal:  J Antimicrob Chemother       Date:  1987-03       Impact factor: 5.790

6.  Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus.

Authors:  M A Sande; M L Johnson
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

7.  Activity of twenty-one antimicrobial agents including l-ofloxacin against quinolone-sensitive and -resistant, and methicillin-sensitive and -resistant Staphylococcus aureus.

Authors:  L R Peterson; I Cooper; K E Willard; C E Fasching; L M Sinn; C J Shanholtzer; D N Gerding
Journal:  Chemotherapy       Date:  1994 Jan-Feb       Impact factor: 2.544

8.  Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis.

Authors:  J M Steckelberg; M S Rouse; B M Tallan; D R Osmon; N K Henry; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

9.  Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis.

Authors:  M A Sande; K B Courtney
Journal:  J Lab Clin Med       Date:  1976-07

10.  Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart.

Authors:  P K Garrison; L R Freedman
Journal:  Yale J Biol Med       Date:  1970-06
View more
  5 in total

1.  Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.

Authors:  H F Chambers; Q Xiang; L L Chow; C Hackbarth
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  Fu-Yu Chiang; Michael Climo
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 3.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

4.  Effective treatment of cephalosporin-rifampin combinations against cryptic methicillin-resistant beta-lactamase-producing coagulase-negative staphylococcal experimental endocarditis.

Authors:  C M Brandt; M S Rouse; B M Tallan; N W Laue; W R Wilson; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

5.  In vivo interactions of continuous flucloxacillin infusion and high-dose oral rifampicin in the serum of 15 patients with bone and soft tissue infections due to Staphylococcus aureus - a methodological and pilot study.

Authors:  Christian Garzoni; Ilker Uçkay; Wilson Belaieff; Dominique Breilh; Domizio Suvà; Elzbieta Huggler; Daniel Lew; Pierre Hoffmeyer; Louis Bernard
Journal:  Springerplus       Date:  2014-06-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.